The public health emergency around COVID-19 has shown that substantial stakeholder (both government and private) funding to de-risk clinical development, manufacturing development, drug supply security and commercialization can incentivize the industry to cooperatively act to develop vaccines, therapies, diagnostics and treatment regimens more quickly than ever before. These stakeholder incentives for collaboration and open innovation can replace traditional intellectual property rewards for biopharmaceutical R&D. The industry already adopted elements of these factors in CivicaRx, Just Biotherapeutics (no longer independent), Audacity Therapeutics, Medicines4Kids (M4K) and others. Join Worth, Kathleen Entwistle, Paul Fehlner, Barbara Handelin and other special guests as we explore how open innovation in medicine will change the future of healthcare.

Featuring: Kathleen Entwistle, Private Wealth Advisor, Morgan Stanley Private Wealth Management, Paul Fehlner, Co-founder & President/CEO, reVision Therapeutics, Inc. and Barbara Handelin, PHD, Co-Founder & CEO, Audacity Therapeutics, PBC

Moderated by: Juliet Scott-Croxford, CEO, Worth

 

REGISTRATION CLOSED

By registering for this event I agree I want to receive news, updates and invitations from Worth using the information provided on this form. I consent to Worth, its affiliates and service providers processing my personal data for these purposes.
Watch Past Webinars: